首页> 外文期刊>Antioxidants and redox signalling >Identification of michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity
【24h】

Identification of michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity

机译:鉴定具有可产生与抗增殖活性相关的强硫氧还蛋白还原酶抑制特性的取代基的以迈克尔受体为中心的药效团

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aims: The role of thioredoxin reductase (TrxR) in tumorigenesis has made it an attractive anticancer target. A systematic approach for development of novel compounds as TrxR inhibitors is currently lacking. Structurally diversified TrxR inhibitors share in common electrophilic propensities for the sulfhydryl groups, among which include the Michael reaction acceptors containing an α,β-unsaturated carbonyl moiety. We aimed to identify features among structurally diversified Michael acceptor-based compounds that would yield a strong TrxR inhibitory character. Results: Structurally dissimilar Michael acceptor-based natural compounds such as isobutylamides, zerumbone, and shogaols (SGs) were found to possess a poor TrxR inhibitory activity, indicating that a sole Michael acceptor moiety was insufficient to produce TrxR inhibition. The 1,7-diphenyl-hept-3-en-5-one pharmacophore in 3-phenyl-3-SG, a novel SG analog that possessed comparable TrxR inhibitory and antiproliferative potencies as 6-SG, was modified to yield 1,5-diphenyl-pent-1-en-3-one (DPPen) and 1,3-diphenyl-pro-1-en-3-one (DPPro, also known as chalcone) pharmacophores. These Michael acceptor-centric pharmacophores, when substituted with the hydroxyl and fluorine groups, gave rise to analogs displaying a TrxR inhibitory character positively correlated to their antiproliferative potencies. Lead analogs 2,2′-diOH-5,5′-diF-DPPen and 2-OH-5-F-DPPro yielded a half-maximal TrxR inhibitory concentration of 9.1 and 10.5 μM, respectively, after 1-h incubation with recombinant rat TrxR, with the C-terminal selenocysteine residue found to be targeted. Innovation: Identification of Michael acceptor-centric pharmacophores among diversified compounds demonstrates that a systematic approach to discover and develop Michael acceptor-based TrxR inhibitors is feasible. Conclusion: A strong TrxR inhibitory character correlated to the antiproliferative potency is attributed to structural features that include an α,β-unsaturated carbonyl moiety centered in a DPPen or DPPro pharmacophore bearing hydroxyl and fluorine substitutions. Antioxid. Redox Signal. 19, 1149-1165.
机译:目的:硫氧还蛋白还原酶(TrxR)在肿瘤发生中的作用使其成为有吸引力的抗癌靶标。当前缺乏开发作为TrxR抑制剂的新型化合物的系统方法。结构上多样化的TrxR抑制剂具有常见的巯基亲电子倾向,其中包括含有α,β-不饱和羰基部分的Michael反应受体。我们旨在鉴定结构多样的基于迈克尔受体的化合物中的特征,这些特征会产生强大的TrxR抑制特性。结果:发现结构不同的基于迈克尔受体的天然化合物(例如异丁酰胺,蛇骨酮和松果酚(SGs))具有较差的TrxR抑制活性,这表明唯一的迈克尔受体部分不足以产生TrxR抑制作用。对3-苯基-3-SG(一种具有与6-SG相当的TrxR抑制和抗增殖能力的新型SG类似物)中的1,7-二苯基-庚-3-烯-5-酮药效团进行了修饰,得到1,5 -diphenyl-pent-1-en-3-one(DPPen)和1,3-diphenyl-pro-1-en-3-one(DPPro,也称为查尔酮)药效团。这些以迈克尔受体为中心的药效基团,当被羟基和氟基团取代时,产生了类似的TrxR抑制特性,与它们的抗增殖能力呈正相关。与重组体温育1小时后,铅类似物2,2'-diOH-5,5'-diF-DPPen和2-OH-5-F-DPPro产生的TrxR抑制半数最大浓度分别为9.1和10.5μM。大鼠TrxR,其C端硒代半胱氨酸残基被靶向。创新:在多种化合物中鉴定以迈克尔受体为中心的药效基团表明,发现和开发基于迈克尔受体的TrxR抑制剂的系统方法是可行的。结论:与抗增殖能力相关的强TrxR抑制特性归因于结构特征,包括位于带有羟基和氟取代基的DPPen或DPPro药效团中的α,β-不饱和羰基部分。抗氧化。氧化还原信号。 19,1149-1165。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号